#ESMO22 Highlights on actionable inflammatory axis for air pollution induced NSCLC

(3:35)

#ESMO22 Highlights on TILs versus ipilimumab in patients with advanced melanoma: The phase 3 study

(3:16)

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study

(2:37)

#ESMO22 Highlights on neoadjuvant ICI in locally advanced dMMR colon cancer: The NICHE-2 study

(2:46)

#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801

(2:22)

#ESMO22 Highlights on ADT duration with post-operative radiotherapy in prostate cancer: RADICALS-HD

(2:21)

#ESMO22 Highlights on pembrolizumab with CRT in locally advanced HNSCC: The KEYNOTE-412 study

(2:17)

#ESMO22 Highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. RCC: COSMIC-313

(2:56)

#ESMO22 Highlights on nirogacestat in patients with progressing desmoid tumours: The DeFi study

(2:56)

LIBRE EXPRESSION DU 22 DÉCEMBRE 2024

(2:23:58)

Cristiano Ronaldo #RESPECT Moment●

(8:30)

BEST MOMENTS - IEM Cologne 2024 | CS2

(17:7)

Val Martello / World Cup | Sprint Men Race Highlights 2024 | ISMF

(10:4)

Val Martello / World Cup | Individual Men Race Highlights 2024 | ISMF

(9:34)

HIGHLIGHTS | Eintracht Frankfurt vs. Mainz (Bundesliga 2024-25)

(8:37)

ISMF World Cup Courchevel 2024 - Sprint Highlights

(3:4)

32ème de Finale de Coupe de France : Le résumé vidéo de EA Guingamp 2-1 SM Caen

(1:55)

$150 STORM SHOWDOWN: The Ultimate NSC Tournament

(5:31:57)

CF Montréal vs. San Jose Earthquakes | Josef Martínez Brace! | Full Match Highlights

(7:16)

#ESMO22 Highlights on the efficacy and safety of fruquintinib in refractory mCRC: The FRESCO-2 study

(3:35)

#ESMO22 Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02

(2:58)

#ESMO22 Highlights on Sotorasib in NSCLC with KRAS G12C mutation: The CodeBreaK 200 study

(2:35)

ESMO22 Highlights: Dr. Jonasch Discusses the COSMIC313 Trial for Kidney Cancer

(1:37)

ESMO22 Highlights: Patient Advocacy

(2:50)

#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS study

(2:30)

ESMO22: Toni Choueiri, MD | Dana-Farber Cancer Institute

(2:1econd)

Immunotherapy and Targeted Treatment for mNSCLC | Neal Ready, MD, PhD | ESMO22 Pennsylvania

(1:21)

New Classifications and Staging in Breast Cancer | Manisha Bahl, MD | ESMO22 Pennsylvania

(51)

ESMO22: Glenn Hanna, MD | Dana-Farber Cancer Institute

(1:43)